-
Posted by
Two Blokes Jul 17 -
Filed in
Stock
-
3 views
In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line despite other big pharma names in this sector. The firm has an attractive balance sheet risk profile, along with proven growth in operating cashflow, but lacks a steady dividend growth long-term or impressive profit margins.
